A detailed history of Lsv Asset Management transactions in Alkermes Plc. stock. As of the latest transaction made, Lsv Asset Management holds 372,400 shares of ALKS stock, worth $10.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
372,400
Previous 327,700 13.64%
Holding current value
$10.5 Million
Previous $7.9 Million 31.97%
% of portfolio
0.02%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.01 - $28.55 $1.03 Million - $1.28 Million
44,700 Added 13.64%
372,400 $10.4 Million
Q2 2024

Aug 06, 2024

BUY
$23.21 - $27.24 $2.68 Million - $3.14 Million
115,300 Added 54.28%
327,700 $7.9 Million
Q1 2024

May 06, 2024

BUY
$26.4 - $32.56 $2.52 Million - $3.11 Million
95,400 Added 81.54%
212,400 $5.75 Million
Q4 2023

Feb 06, 2024

BUY
$23.37 - $28.68 $2.73 Million - $3.36 Million
117,000 New
117,000 $3.25 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.63B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Lsv Asset Management Portfolio

Follow Lsv Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.